Sesen Bio Inc.

Sesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. It offers chimeric antigen receptor (CAR)-macrophages, a cell therapy platform focusing on the treatment of solid tumors. The company was founded by Michael Klichinsky and Saar Gill in April 2016 and is headquartered in Philadelphia, PA.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN) today reported operating results for the second quarter ended June 30, 2022. During the quarter, the Company paused clinical development of its lead asset, Vicineum™ for the treatment of non-muscle invasive bladder cancer (NMIBC), and turned its primary focus to the assessment of potential strategic alternatives with the goal of maximizing shareholder value, which it believes will be complete by the end of 2022. Business Updates On Jul

Sesen Bio Reports Second Quarter 2022 Financial Results and Business Update

Sesen Bio's (SESN) Q2 performance is likely to reflect cost savings from the company's restructuring plans as the company continues to seek a potential partner for the further development of Vicineum.

What's in the Cards for Sesen Bio's (SESN) Q2 Earnings?

Sesen Bio (SESN) decides to pause the development of Vicineum in the United States. It also ended its 2016 licensing agreement with Roche in exchange for an upfront payment of $40 million.

Sesen (SESN) Halts Bladder Cancer Drug Development, Stock Down

Sesen Bio Inc (NASDAQ: SESN) shares are trading lower by 28.9% at $0.66 Monday morning after the company announced that it has made the decision to voluntarily pause further development in the US of its lead asset, Vicineum. What Happened?

Why Shares Of Sesen Bio Are Down 28% Today

Based on a thorough reassessment Sesen Bio Inc (NASDAQ: SESN) has decided to voluntarily pause further development in the U.S. of its lead asset, Vicineum, for non-muscle invasive bladder cancer (NMIBC). The decision was based on a reassessment of the incremental development.

Sesen Bio Pauses Clinical Development Of Its Lead Bladder Cancer Candidate In US

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN) today announced that it has made the strategic decision to voluntarily pause further development in the US of its lead asset, Vicineum. The decision was based on a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase 3 clinical trial for the treatment of non-muscle invasive bladder cancer (NMIBC), following recent discussions with the US Food & Drug Admi

Sesen Bio Announces Strategic Decision to Pause Clinical Development of Vicineum™ in the US

Senseonics Holdings

Titan Pharma

Use these tips for finding penny stocks in different industries in 2022 The post Which Industries Are Penny Stocks Investors Watching Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Which Industries Are Penny Stocks Investors Watching Right Now

Brickell Biotech Inc

Cardiff Oncology

MEI Pharma

Biotech penny stocks to watch in June. The post Top Penny Stocks To Buy?

Top Penny Stocks To Buy? 4 Biotech Stocks To Watch Now

Athersys

LiveOne

Stocks Under $1 To Watch This Week. The post Top Penny Stocks To Buy For Under $1?

Top Penny Stocks To Buy For Under $1? 3 To Watch This Week

Alkermes

Regeneron Pharmaceuticals

Sanofi

The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.

Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication (Revised)

Wilmington, Delaware--(Newsfile Corp. - May 18, 2022) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Sesen Bio, Inc. (NASDAQ: SESN) on behalf of stockholders.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-sesen-bio-inc.To contact Seth D. Rigrodsky or Gina M. Serra cost free, call or text (302) 295-5310 or email info@rl-legal.com.Rigrodsky Law, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on...

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Sesen Bio, Inc.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported operating results for the first quarter ended March 31, 2022. During the quarter, the Company continued to engage with the US Food and Drug Administration (FDA) to identify an anticipated regulatory path toward potential resubmission of a Biologics License Application (BLA) for Vicineum™ for the treat

Sesen Bio Reports First Quarter 2022 Financial Results and Business Update

Evoke Pharma

Globalstar

IT Tech Packaging Inc

Kala Pharmaceuticals

Kiromic Biopharma

Pingtan Marine Enterprise

PolarityTE Inc

Sonim Technologies Inc

Top penny stocks under $1 to watch in May. The post 10 Top Penny Stocks To Buy For Under $1 May 2022 Edition appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10 Top Penny Stocks To Buy For Under $1 May 2022 Edition

Mullen Automotive

Statera Biopharma Inc

Why these three penny stocks shot up during trading on May 5th The post 3 Penny Stocks That Pushed Up During Trading Today  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks That Pushed Up During Trading Today

Clarus Therapeutics Holdings

Hot penny stocks under $1 to watch this week. The post Hot Penny Stocks To Buy For Under $1 This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks To Buy For Under $1 This Week

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that it has initiated a process to review strategic alternatives with the goal of maximizing shareholder value. Potential strategic alternatives to be explored and evaluated during the review process may include the sale of the Company, a merger, acquisition or other business combination, a strategic

Sesen Bio Provides Strategic Update

Akebia Therapeutics

Borqs Technologies

Penny stocks under $1 to watch right now. The post Best Penny Stocks To Buy Now?

Best Penny Stocks To Buy Now? 5 Stocks Under $1 To Watch In April

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported operating results for the fourth quarter and full year ended December 31, 2021. During the fourth quarter, the Company worked with the US Food and Drug Administration (FDA) to identify an anticipated regulatory path toward potential resubmission of a Biologics License Application (BLA) for the Company

Sesen Bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Anticipated Regulatory Path Forward for the Company's Lead Product Candidate, Vicineum™

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the appointments of Minori Rosales, M.D., Ph.D. as Chief Development Officer as of January 24, 2022 and Stephanie Vigue as Director of Finance as of January 17, 2022. “We are pleased to welcome these highly qualified new employees to our team,” said Dr. Thomas Cannell, president and chief executive o

Sesen Bio Further Enhances Team with Key Hires

Document Security Systems

GEE Group

SNDL Inc.

Surgalign Holdings, Inc.

Waitr Holdings Inc

These penny stocks trading for under $1 per share all have strong chances of delivering stunning returns in the coming year. The post 6 of the Best Penny Stocks Under $1 to Buy Now for 2022 appeared first on InvestorPlace.

6 of the Best Penny Stocks Under $1 to Buy Now for 2022

Gran Tierra Energy

Powerbridge Technologies Co Ltd

Palatin Technologies

Cheap penny stocks to watch this week. The post 4 Penny Stocks To Buy For Under $1 On Webull appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Penny Stocks To Buy For Under $1 On Webull

The stock price of Sesen Bio Inc (NASDAQ: SESN) fell by 17.58% today. This is why it happened.

Sesen Bio Stock (SESN): Why The Price Substantially Fell Today

The company's hopeful words about its pipeline drug fell on deaf ears.

Why Sesen Bio Stock Got Slammed Today

Sesen Bio Inc (NASDAQ: SESN) has outlined its anticipated regulatory path forward for Vicineum for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) following its Clinical Type A meeting with the FDA. Following the meeting, the Company has agreed to conduct a randomized clinical trial assessing the safety and efficacy of Vicineum compared to investigators' choice of intravesical chemotherapy.

Sesen Bio To Conduct Additional Trial For Potential Resubmission Of Vicineum In Bladder Cancer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced its anticipated regulatory path forward for Vicineum™ for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) following its Clinical Type A meeting with the US Food and Drug Administration (FDA), which occurred on December 8, 2021 (Clinical Type A Meeting). Following the produ

News for Sesen Bio Inc. Stock (SESN)